Premium
4 Gy radiotherapy in 6 patients with orbit marginal zone lymphoma: A small case series
Author(s) -
Graeff E.
Publication year - 2016
Publication title -
acta ophthalmologica
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.534
H-Index - 87
eISSN - 1755-3768
pISSN - 1755-375X
DOI - 10.1111/j.1755-3768.2016.0538
Subject(s) - medicine , lacrimal gland , radiation therapy , orbit (dynamics) , marginal zone , lymphoma , diplopia , radiology , rituximab , surgery , pathology , b cell , antibody , engineering , immunology , aerospace engineering
Purpose To demonstrate therapeutic approach with low dose radiotherapy of 4 Gy in 6 cases of marginal zone lymphoma (2 lacrimal gland cases, 1 conjunctival case and 3 orbital cases itself) Methods Small case series of 6 patients with ocular marginal zone lymphoma, including diagnostic and therapeutic options Results In 6 patients (58–86 years) a marginal zone lymphoma of the orbit was diagnosed. A proptosis of the eye could be observed in one patient with lacrimal gland tumour as well as in three patients with orbital lesions itself. Two patients showed additional eye movement retraction accompanied by diplopia. In addition to a thorough ophthalmological examination, the staging of patient included ultrasound of the orbit, MRI of the head, gastroscopic examination and a PET‐CT of the whole body was performed. In all cases the diagnosis was made by ocular pathology. A focal radiotherapy with 4 Gy in two fractions was the only treatment in 5 cases. In one case a combination with additional systemical rituximab was necessary. A regression of all lesions could be observed and no tumour relapses occured until 7–29 months later. Conclusions In cases of orbit MALT lymphoma a gold standard radiotherapy of 30 Gy in 15 fractions was established. However in our small case series of 6 patients a complete regression of tumour mass was shown using 4 Gy in two fractions. Depending on the general state of the patient a reduced radiation therapy remains a usefull alternative.